Key Segmentation:
By Drug Class
-
Monoclonal Antibodies
-
Bispecific & Multispecific Antibodies
-
Oral Small Molecules & Peptides
-
Cytokines & Fusion Proteins
-
Cell & Gene Therapies
By Indication
-
Rheumatoid Arthritis & Spondyloarthritis
-
Inflammatory Bowel Disease
-
Psoriasis & Atopic Dermatitis
-
Asthma & Respiratory Diseases
-
Neurological Autoimmune Diseases
-
Other Indications
By Route of Administration
-
Subcutaneous
-
Intravenous
-
Oral
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Drug Class X Indication)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Key players include AbbVie Inc., Johnson & Johnson, Sanofi S.A., Regeneron Pharmaceuticals, Inc., and Eli Lilly and Company, among others.
Key opportunities include oral peptides and small molecules, anti-TL1A therapies for inflammatory bowel disease, bispecific antibodies, and pediatric label extensions across established franchises.
The primary growth factor is the rising burden of autoimmune and inflammatory diseases, combined with demand for more precise, better-tolerated therapies with novel mechanisms.
By drug class, the Monoclonal Antibodies segment dominates the Next-Generation Immunology Drugs Market with approximately 58.40% share in 2025.
North America dominates the Next-Generation Immunology Drugs Market with approximately 44.60% share in 2025, while Asia-Pacific is the fastest-growing region with a CAGR of approximately 9.35%.
